Gene

HLA-DRA

major histocompatibility complex, class II, DR alpha

Explore in graph →CI-GENE-00004471HGNC:4947 ENSG00000204287 NCBI 3122 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
HLA-DRA EXPRESSION1
Atezolizumab + Nivolumab + PembrolizumabSubstitutes	Cutaneous MelanomaALIAS	Predictive	B	Supports Sensitivity Response	3	accepted	EID985 Melanoma patients treated with Anti-PD1 or anti-PD-L1(nivolumab, pembrolizumab, MPDL3280A) therapy were analyzed for expression of HLA-DRA (the primary antigen-presenting molecule of the MHC-II pathwa… (full text at CIViC) PMID 26822383 · Johnson et al., 2016 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (2)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved2 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Germ Cell Tumors and Shared Leukemias (MSK, J Clin Invest 2020) gct_msk_2020	unmapped	Ssm	2	13	15.4%

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.
· Nat Commun · 2016 · PMID 26822383 · validated civic_curation pubmed